title: Splenectomy for an adult patient with refractory secondary hemophagocytic lymphohistiocytosis.
abstract: Treatment regimens of secondary hemophagocytic lymphohistiocytosis (sHLH) are complicated and individualized. CHOP regimen is well known for the treatment of adult sHLH, but it was not so effective for the 56-year-old male patient in our study. Splenomegaly, one of clinical manifestations of HLH, has urged us to investigate the role of splenectomy in HLH patients. Splenectomy is not only beneficial to confirm the underlying diseases, but also beneficial for the treatment of HLH. Here, we present a case diagnosed as sHLH who has recovered from HLH following comprehensive treatment based on splenectomy. The therapeutic value of splenectomy in sHLH needs further study.
authors.affiliation: Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, 300, Guangzhou Road, Nanjing, Jiangsu 210029, China.
authors.forename: Li-Juan
authors.initials: LJ
authors.lastname: Zhang
authors.forename: Su-Jiang
authors.initials: SJ
authors.lastname: Zhang
authors.forename: Ji
authors.initials: J
authors.lastname: Xu
authors.forename: Jian-Yong
authors.initials: JY
authors.lastname: Li
authors.forename: Ling-Ling
authors.initials: LL
authors.lastname: Wang
authors.forename: Yi-Xin
authors.initials: YX
authors.lastname: Hu
authors.forename: Hong-Xia
authors.initials: HX
authors.lastname: Qiu
authors.forename: Yong-Qian
authors.initials: YQ
authors.lastname: Shu
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D004351:Drug Resistance; D006801:Humans; D051359:Lymphohistiocytosis, Hemophagocytic / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D013156:Splenectomy; D013163:Splenomegaly / Q000209:etiology; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone